By utilising best practice guidelines, building relationships with patients and gaining their trust, the haematology community delivers the best care possible.

In the words of our Past Presidents

‘…the focus is very much now on developing targeted therapies because obviously the target of our efforts is to benefit the patients.’
Daniel Catovsky, BSH President 1996 - 1997

‘…within the area of haemato-oncology, I've absolutely no doubt the greatest advance has been in supportive care.’
David Linch, BSH President 2009 - 2010

‘…the patient is the centre of everything.’
Graham Jackson, BSH President 2013 - 2014

Highlights from the haematology timeline

Our timeline highlights many examples of enhancing care, including:

  • 2011 Fatigue recognised as important symptom of ITP
  • 2000s Haemovigilance: SHOT is the gold standard
  • 1979 Specialist centres for haemoglobin disorders opened
  • 1967 Launch of an external quality assessment programme

Browse the full timeline for more examples using the link below or in the right-hand menu.

Reflections from the haematology community

In preparation for our 60th anniversary, we invited members of the haematology community to share with us their thoughts and reflections. 

Find out more about our anniversary video contributors.

It is not too late to participate – please send your story to janet@b-s-h.org.uk.

Kris Griffin speaks about his experience with his consultant
Kris Griffin speaks about his experience with his consultant
Kris Griffin speaks about his experience changing from imatinib to dasatinib
Kris Griffin speaks about his experience changing from imatinib to dasatinib
Kris Griffin explains how his chronic myeloid leukaemia became undetectable
Kris Griffin explains how his chronic myeloid leukaemia became undetectable
Sally Barrington: PET and bone marrow biopsy
Sally Barrington: PET and bone marrow biopsy
Robert Marcus: A key development in the treatment of follicular lymphoma
Robert Marcus: A key development in the treatment of follicular lymphoma
Robert Marcus: Future direction of the treatment of follicular lymphoma
Robert Marcus: Future direction of the treatment of follicular lymphoma
Robert Marcus: What makes you passionate about the treatment of follicular lymphoma?
Robert Marcus: What makes you passionate about the treatment of follicular lymphoma?
Robert Marcus: Where do you see the treatment of follicular lymphoma in ten years?
Robert Marcus: Where do you see the treatment of follicular lymphoma in ten years?
Peter Johnson: One key development in the treatment of Hodgkin's lymphoma, and what it has meant to the treatment of patients
Peter Johnson: One key development in the treatment of Hodgkin's lymphoma, and what it has meant to the treatment of patients
Peter Johnson: Major developments in the treatment of Hodgkin's lymphoma
Peter Johnson: Major developments in the treatment of Hodgkin's lymphoma
Peter Johnson: What do you see as the future of the treatment of Hodgkin's lymphoma?
Peter Johnson: What do you see as the future of the treatment of Hodgkin's lymphoma?
Peter Johnson: What would the improvement you would like to see in the treatment of Hodgkin's lymphoma mean to patients?
Peter Johnson: What would the improvement you would like to see in the treatment of Hodgkin's lymphoma mean to patients?
Peter Johnson: What makes you passionate about the treatment of Hodgkin's lymphoma?
Peter Johnson: What makes you passionate about the treatment of Hodgkin's lymphoma?
Peter Johnson: What would you say to a medical student to encourage them to specialise within your field?
Peter Johnson: What would you say to a medical student to encourage them to specialise within your field?
Peter Johnson: What interests you most about the treatment of Hodgkin's lymphoma?
Peter Johnson: What interests you most about the treatment of Hodgkin's lymphoma?
Ted Tuddenham: What are your biggest hopes for haematology over the next 60 years?
Ted Tuddenham: What are your biggest hopes for haematology over the next 60 years?
Heidi Doughty: What do you think is the impact on military transfusion on wider healthcare?
Heidi Doughty: What do you think is the impact on military transfusion on wider healthcare?
Anne Lennard: What impact will machine learning and AI have on your field in the future?
Anne Lennard: What impact will machine learning and AI have on your field in the future?
Anne Lennard: What makes you passionate about the treatment of T-cell lymphoma?
Anne Lennard: What makes you passionate about the treatment of T-cell lymphoma?
Keith Hyde: What do you believe were the key innovations in haematology in the 1980s?
Keith Hyde: What do you believe were the key innovations in haematology in the 1980s?
Keith Hyde: What are the most significant developments happening right now in haematology?
Keith Hyde: What are the most significant developments happening right now in haematology?
Sue Pavord: What have been the major developments in your subspecialty?
Sue Pavord: What have been the major developments in your subspecialty?
Sue Pavord: Which aspects of working in haematology have given you the greatest satisfaction?
Sue Pavord: Which aspects of working in haematology have given you the greatest satisfaction?
Barbara Bain: What are your biggest hopes for haematology over the next 60 years?
Barbara Bain: What are your biggest hopes for haematology over the next 60 years?
Barbara Bain: Which aspects of working in haematology have given you the greatest satisfaction?
Barbara Bain: Which aspects of working in haematology have given you the greatest satisfaction?
Jamie Saunders: Where do you believe haematology will be in 60 years' time?
Jamie Saunders: Where do you believe haematology will be in 60 years' time?
Jamie Saunders: Which aspects of working in haematology have given you the greatest satisfaction?
Jamie Saunders: Which aspects of working in haematology have given you the greatest satisfaction?
Cathy Burton: What do you believe are the key innovations in immunohistochemistry and molecular diagnostics in the past 60 years?
Cathy Burton: What do you believe are the key innovations in immunohistochemistry and molecular diagnostics in the past 60 years?
Cathy Burton: What are the most significant developments happening right now in immunohistochemistry and molecular diagnostics?
Cathy Burton: What are the most significant developments happening right now in immunohistochemistry and molecular diagnostics?
Lorna Williamson: an overview of where the treatment of transfusion medicine was when you first started working in the field
Lorna Williamson: an overview of where the treatment of transfusion medicine was when you first started working in the field
Lorna Williamson: Is there anything you would like to add about transfusion medicine that you think viewers may find interesting?
Lorna Williamson: Is there anything you would like to add about transfusion medicine that you think viewers may find interesting?
Lorna Williamson: What do you see as the future in the treatment of transfusion medicine?
Lorna Williamson: What do you see as the future in the treatment of transfusion medicine?
Jackie Green: Could you tell us more about the role of a haematology nurse?
Jackie Green: Could you tell us more about the role of a haematology nurse?
Jackie Green: What do you believe are the key innovations in haematology in the past 60 years?
Jackie Green: What do you believe are the key innovations in haematology in the past 60 years?
Jackie Green: What do you consider to have been the greatest moment within your career to date?
Jackie Green: What do you consider to have been the greatest moment within your career to date?
Jackie Green: Which aspects of working in haematology have given you the greatest satisfaction?
Jackie Green: Which aspects of working in haematology have given you the greatest satisfaction?
Imelda Bates: What are the most significant developments happening right now in haematology in developing countries?
Imelda Bates: What are the most significant developments happening right now in haematology in developing countries?
Shivir Moosai: What would you like to achieve within your career in haematology?
Shivir Moosai: What would you like to achieve within your career in haematology?
Shivir Moosai: What advice would you give to people considering starting a career in haematology?
Shivir Moosai: What advice would you give to people considering starting a career in haematology?
Shivir Moosai: What do you believe are the key innovations in haematology in the past 60 years?
Shivir Moosai: What do you believe are the key innovations in haematology in the past 60 years?
Shivir Moosai: Which aspects of working in haematology have given you the greatest satisfaction?
Shivir Moosai: Which aspects of working in haematology have given you the greatest satisfaction?
Jim Murray: What advice would you give to people considering starting a career in haematology?
Jim Murray: What advice would you give to people considering starting a career in haematology?
Jim Murray: Interaction with patients
Jim Murray: Interaction with patients
Jim Murray: The way that we communicate with patients
Jim Murray: The way that we communicate with patients
Jim Murray: The most significant developments happening right now in haematology
Jim Murray: The most significant developments happening right now in haematology

Click on the buttons below:

The views expressed in the material filmed for the anniversary are those of the participants involved and do not necessarily represent the views of the British Society for Haematology.

Filming took place during the second half of 2019 and the start of 2020, prior to the Covid-19 pandemic.